Beyond CD19: New Strategies Emerge for Resistant B-Cell ALL (Blood Cancers Today) - Sep 16, 2026 - "'One option could be to deliver blinatumomab subcutaneously in the relapsed setting, so we can deliver a much higher dose,' explained Dr. Logan. 'This appears to result in very high response rates, even among patients who had previously received continuous intravenous infusion blinatumomab.' Dr. Logan added that toxicity is a problem with this approach, with a serious adverse event rate of 80%, mostly due to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)."
Media quote
|